Pilot trial of etanercept in the treatment of inclusion-body myositis

Inclusion-body myositis (IBM) is an inflammatory muscle disease that has proven resistant to treatment. Tumor necrosis factor molecules have been detected in muscle biopsies from patients with IBM. Etanercept is a TNFα receptor fusion protein that binds and inactivates tumor necrosis factor. Nine patients were treated with etanercept at a dose of 25 mg, two times a week for an average of 17 ± 6.1 months. Each patient was evaluated using quantitative strength testing. Their data were compared to two different control groups. The first control group consisted of patients who participated in trials of beta-interferon-1A and had received placebo. There was no significant difference. The second control group was a natural history cohort of IBM patients. There was no statistically significant difference between the treated group and the natural history group at 6 and 12 months when looking at elbow flexors, or 6 months when looking at hand grip. In the treated patients there was a small but significant improvement (p = 0.002) in handgrip at 12 months.

[1]  Pellissier,et al.  Local expression of cytokines in idiopathic inflammatory myopathies , 1998, Neuropathology and applied neurobiology.

[2]  M. Dalakas,et al.  Inclusion body myositis and myopathies , 1997, Journal of the Neurological Sciences.

[3]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[4]  M. Toepfer,et al.  High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study , 2000, Journal of Neurology.

[5]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[6]  W. Declercq,et al.  Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies 1 This paper was presented at the 50th Annual Meeting of the American Academy of Neurology, Minneapolis, MN, USA, April 1998. 1 , 1999, Neuromuscular Disorders.

[7]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[8]  S. Spector,et al.  A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM , 2001, Neurology.

[9]  A. Engel,et al.  Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells , 1984, Annals of neurology.

[10]  Randomized pilot trial of high-dose βINF-1a in patients with inclusion body myositis , 2004, Neurology.

[11]  J. Mendell,et al.  Inclusion body myositis , 1995, Neurology.

[12]  D. Furst,et al.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.

[13]  A. Zwinderman,et al.  Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo , 2002, Annals of neurology.

[14]  P H Plotz,et al.  The Treatment of Inclusion Body Myositis: A Retrospective Review and a Randomized, Prospective Trial of Immunosuppressive , 1993, Medicine.

[15]  Lippincott Williams Wilkins,et al.  A Prospective, Quantitative Study of the Natural History of Facioscapulohumeral Muscular Dystrophy (FSHD) , 1997, Neurology.

[16]  A. Engel,et al.  Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. , 1989, Human pathology.

[17]  A. Engel,et al.  Expression of Cell Adhesion Molecules in Inflammatory Myopathies and Duchenne Dystrophy , 1994, Journal of neuropathology and experimental neurology.